C4 Therapeutics Income Statement (2019-2026) | CCCC

Income Statement Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Revenue & cost
Revenue (Quarter)
9.78M8.50M20.08M7.65M13.83M6.75M2.85M3.76M2.66M11.07M3.26M3.04M12.01M15.36M5.18M7.24M6.46M11.23M11.02M6.15M
Operating items
Research & Development (Quarter)
23.29M24.30M26.55M26.20M31.32M29.66M30.65M29.04M29.93M28.35M30.39M22.53M23.75M31.84M32.51M27.07M26.20M25.99M24.98M24.61M
Selling, General & Administrative (Quarter)
8.61M8.45M8.78M12.82M9.89M9.58M10.49M10.95M10.31M10.53M10.30M10.29M9.70M11.77M10.37M9.33M8.77M8.92M9.18M9.33M
Other Operating Expenses (Quarter)
2.44M10.73M
Operating Expenses (Quarter)
31.90M32.75M35.33M39.02M41.22M39.24M41.15M39.99M40.23M38.88M40.69M35.26M33.45M43.61M42.89M36.40M34.96M45.64M34.16M33.94M
Operating Income (Quarter)
-22.12M-24.25M-15.26M-31.37M-27.38M-32.49M-38.29M-36.23M-37.57M-27.81M-37.43M-32.22M-21.44M-28.24M-37.71M-29.16M-28.50M-34.41M-23.14M-27.79M
EBIT (Quarter)
-22.12M-24.25M-15.26M-31.37M-27.38M-32.49M-38.29M-36.23M-37.57M-27.81M-37.43M-32.22M-21.44M-28.24M-37.71M-29.16M-28.50M-34.41M-23.14M-27.79M
Non-operating items
Non Operating Investment Income (Quarter)
0.03M-0.09M-0.62M-2.88M-0.93M-0.83M1.27M1.67M0.70M0.87M0.78M-0.25M-0.06M0.90M-0.40M-0.01M-0.07M
Interest & Investment Income (Quarter)
0.07M0.11M0.14M0.28M0.51M1.08M1.71M2.05M2.25M2.56M2.95M3.86M3.73M3.58M3.27M2.84M2.48M2.25M2.78M2.66M
Other Non Operating Income (Quarter)
-0.62M
Non Operating Income (Quarter)
-0.46M-0.43M-0.40M-0.25M-0.03M0.53M1.11M1.45M1.65M1.77M2.95M3.86M3.73M3.58M3.27M2.84M2.48M2.25M2.78M2.66M
Net income details
EBT (Quarter)
-22.58M-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-26.03M-34.48M-28.36M-17.72M-24.67M-34.44M-26.32M-26.02M-32.17M-20.36M-27.45M
Tax Provisions (Quarter)
1.00M0.28M0.13M
Profit After Tax (Quarter)
-22.58M-24.77M-16.28M-31.62M-27.41M-31.96M-37.21M-34.78M-35.92M-26.17M-30.74M-28.36M-17.72M-23.77M-34.98M-26.32M-26.02M-32.05M-20.49M-25.50M
Income from Non-Controlling Interests (Quarter)
0.90M-0.01M0.12M-0.37M
Income from Continuing Operations (Quarter)
-22.58M-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-27.45M
Consolidated Net Income (Quarter)
-22.58M-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-27.45M
Income towards Parent Company (Quarter)
-22.58M-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-27.45M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-22.58M-24.68M-15.66M-31.62M-128.67M-31.96M-37.19M-34.78M-35.92M-27.04M-34.76M-28.36M-17.72M-24.67M-34.57M-26.32M-26.02M-32.17M-20.36M-27.45M
Additional items
EPS (Basic) (Quarter)
-0.51-0.51-0.34-0.65-2.64-0.65-0.76-0.71-0.73-0.55-0.70-0.41-0.26-0.35-0.50-0.37-0.37-0.44-0.25-0.22
EPS (Diluted) (Quarter)
-0.51-0.51-0.34-0.65-2.64-0.65-0.76-0.71-0.73-0.55-0.70-0.41-0.26-0.35-0.50-0.37-0.37-0.44-0.25-0.22
Shares Outstanding (Quarter)
43.86M48.49M46.04M48.73M48.82M48.92M48.86M49.03M49.06M49.21M49.64M68.43M68.81M69.63M69.37M70.83M71.01M72.56M82.89M126.07M
Shares Outstanding (Diluted) (Quarter)
43.86M48.49M46.04M48.73M48.82M48.92M48.86M49.03M49.06M49.21M49.64M68.43M68.81M69.63M69.37M70.83M71.01M72.56M82.89M126.07M
EBITDA (Quarter)
-22.12M-24.25M-15.26M-31.37M-27.38M-32.49M-38.29M-36.23M-37.57M-27.81M-37.43M-32.22M-21.44M-28.24M-37.71M-29.16M-28.50M-34.41M-23.14M-27.79M
Interest Expenses (Quarter)
4.84M16.63M0.24M103.88M101.79M99.70M-3.46M2.48M1.79M0.91M-5.43M2.18M0.45M0.04M-6.61M2.25M0.08M0.01M0.06M2.32M
Tax Rate (Quarter)
-3.85%-0.81%-0.38%